Journal
SEMINARS IN LIVER DISEASE
Volume 32, Issue 1, Pages 30-38Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0032-1306424
Keywords
Nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; insulin resistance; hepatocellular carcinoma
Categories
Funding
- Genentech
- Merck
- BMS
- Rottapharm
- Mochida
Ask authors/readers for more resources
Nonalcoholic fatty liver disease (NAFLD) is easily themost common cause of chronic liver disease in the United States (U. S.) as the hepatic manifestation of the metabolic syndrome. Although only 5 to 20% of patients with NAFLD are generally considered to meet criteria for nonalcoholic steatohepatitis (NASH), with its inherent risk for progression to cirrhosis, this still represents an alarmingly large number of individuals. The exponentially growing rates of hepatocellular carcinoma (HCC) in the U. S. may be partially attributable to increased numbers of NASH cirrhotics, although recent evidence has suggested that NAFLD may directly promote hepatic carcinogenesis independent of cirrhosis. This review focuses on HCC in noncirrhotic NASH with an emphasis on clinical presentation, pathogenesis, and implications for screening.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available